A Phase II, Single-Arm, Feasibility Study of Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Trial Profile

A Phase II, Single-Arm, Feasibility Study of Dose Dense Doxorubicin and Cyclophosphamide (AC) Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Eribulin (Primary) ; Cyclophosphamide; Doxorubicin; Growth factors
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 12 Dec 2015 Primary endpoint of feasibility of the regimen for each individual subject has not been met, according to results presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 01 Jul 2015 Planned primary completion date changed from 1 May 2015 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top